FIG 3.

Cumulative incidence of fluoropyrimidine-related grade 3+ toxicities and hospitalizations stratified by genotype groups in 442 patients. Cumulative incidence was estimated as 1—Kaplan-Meier survival estimate, and log-rank test was used to compare between genotype groups. All subjects with follow-up time >110 days were censored observations and were truncated at 110 days. (A) Grade 3+ toxicities occurred earlier and at a significantly higher rate in reactive carriers compared with pretreatment carriers and wild-type patients (P < .001). (B) Hospitalizations also occurred earlier and at a significantly higher rate in reactive carriers compared with pretreatment carriers and wild-type patients (P < .001).